Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature currently requires accessing the site using the built-in Safari browser.
You are using an out of date browser. It may not display this or other websites correctly. You should upgrade or use an alternative browser.
Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page
Hello,
I would like to invite clinical research professionals working within a biotechnology company or an academic institute on a clinical trial involving gene therapy in the US to participate in an ongoing research study!
The goal of this research study is to measure your awareness and...
Carolyn Rasmussen
Thread
awareness
clinicaltrials
gene therapy
genetic counseling
genetic counselor
mount sinai
research
survey
Last week, Gilead failed in Phase 3 clinical trial for NASH drug. Today, Intercept has become the first player in the NASH area to complete a pivotal Phase 3 study in patients with liver fibrosis.
anonymous
Thread
clinicaltrials
drug
europe
fda
gilead
gilead sciences
intercept pharmaceuticals
liver fibrosis
nash
viking therapeutics
After announcing positive results for the treatment of cystic fibrosis, Proteostasis Therapeutics stock skyrocketed more than 400% and reached the double-digit mark after 18 months.
https://news.alphastreet.com/proteostasis-therapeutics-stock-skyrockets-on-positive-cystic-fibrosis-trial-results/
In the past two weeks, Celgene has reported positive results from 3 clinical trials. This includes two studies with its partner Acceleron. https://news.alphastreet.com/celgene-gets-a-booster-shot-from-recent-positive-clinical-trial-results/
Hello, my colleagues and I at Columbia University are collecting data on cancer clinical trials to better understand the needs of the healthcare community. Please respond to the below questions and thank you in advance for taking the time to complete this questionnaire...